We demonstrated that a low expression level of PHF2 and C/EBPα was significantly correlated with a larger tumour size, higher WHO/ISUP grade, high pM stage, advanced pTNM stage, and shorter overall, cancer-specific and progression-free survival times. The gene discussed is PHF2; the disease is neoplasm.